ENSYSCE BIOSCIENCES INC (ENSC)

US2936024056 - Common Stock

0.5586  +0 (+0.05%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ENSYSCE BIOSCIENCES INC

NASDAQ:ENSC (4/24/2024, 7:00:01 PM)

0.5586

+0 (+0.05%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap1.76M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ENSC Daily chart

Company Profile

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The company is headquartered in La Jolla, California and currently employs 7 full-time employees. The company went IPO on 2017-12-01. The firm is engaged in developing solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. The firm is using its proprietary technology platforms to develop safer prescription drugs. The firm's development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology - the Trypsin Activated Abuse Protection, (the TAAP platform), and an over-dose protection opioid prodrug technology - the Multi-Pill Abuse Resistant, (MPAR platform). The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR platform when combined with the Company’s TAAP prodrugs is designed not only to seek to prevent abuse of prescription drugs but also to reduce overdose occurrences.

Company Info

ENSYSCE BIOSCIENCES INC

7946 Ivanhoe Avenue, Suite 201

La Jolla CALIFORNIA

P: 18582634196

CEO: Daniel B. Silvers

Employees: 7

Website: https://ensysce.com/

ENSC News

News Imagea month ago - InvestorPlaceFSR Stock: The $150 Million Reason Fisker Shares Are Moving Today

Fisker stock is on the move Monday as FSR investors learn about the EV company securing an additional $150 million in funding.

News Imagea month ago - InvestorPlaceENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023

ENSC stock results show that Ensysce Biosciences missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

News Imagea month ago - BusinessInsiderENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ensysce Biosciences (NASDAQ:ENSC) just reported results for the fourth quarter ...

News Image2 months ago - Seeking AlphaEnsysce Biosciences falls on exercise of warrants for $4.7M gross proceeds (NASDAQ:ENSC)

Ensysce Biosciences (ENSC) experienced a 4% drop in premarket trading as the biotech announced agreements for the immediate exercise of outstanding...

News Image3 months ago - Seeking AlphaEnsysce rallies 22% on FDA update for overdose-resistant opioid (NASDAQ:ENSC)

Ensysce (ENSC) stock closed 22% higher Tuesday after the company said it had received FDA breakthrough therapy designation for its overdose-resistant opioid drug candidate.

News Image3 months ago - Seeking AlphaEnsysce Biosciences files to sell common stock, warrants (NASDAQ:ENSC)

Ensysce Biosciences files for a prospectus regarding the sale of its common stock and common warrants, but notes that it is not an offer to sell these...

ENSC Twits

Here you can normally see the latest stock twits on ENSC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example